Final Results of a Phase I/II Trial of Carfilzomib plus R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

被引：0
|
作者：
Hill, Brian T. [1 ]
Torka, Pallawi [2 ]
Hernandez-Ilizaliturri, Francisco J. [3 ]
Dean, Robert M. [4 ]
Jagadeesh, Deepa [1 ]
Karamlou, Kasra [1 ]
Fu, Chieh-Lin [5 ]
Winter, Allison [4 ]
Krauspe, Ethan [1 ]
Zhou, Jonathan [1 ]
Brooks, Taylor R. [1 ]
Kacar, Merve [6 ]
Tomlinson, Ben K. [7 ]
Cooper, Brenda W. [7 ]
Li, Hong [8 ]
Jia, Xuefei [1 ]
Chen, Yanwen [1 ]
Thomas, Jenna [1 ]
Caimi, Paolo F. [4 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Dept Med, Montvale, NJ USA
[3] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[4] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA
[5] Cleveland Clin Florida, Maroone Canc Ctr, Weston, FL USA
[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[7] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[8] Cleveland Clin, Dept Biostat & Quantitat Hlth Sci, Cleveland, OH 44106 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-173943
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Cost of Disease Progression after Frontline (1L) R-CHOP in Diffuse Large B-Cell Lymphoma (DLBCL)
    Wang, Rongrong
    Roth, Josh
    Ng, Carmen
    Hossain, Farah
    Li, Jia
    Masaquel, Anthony
    BLOOD, 2021, 138
  • [22] Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL.
    Doner, Kevin
    Flinn, Ian W.
    Ulrich, Brian K.
    Noga, Stephen J.
    Chowhan, Naveed M.
    Papish, Steven W.
    Mahmood, Tallat
    Reeves, James A.
    Di Bella, Nicholas J.
    Robbins, Gerald J.
    Ramchandren, Radhakrishnan
    Aung, Sein
    Lawler, William
    Parasuraman, Sudha
    Corvez, Maria M.
    Mulligan, George
    Leonard, John P.
    BLOOD, 2010, 116 (21) : 748 - 748
  • [23] RANDOMIZED PHASE II STUDY OF R-CHOP PLUS ENZASTAURIN VERSUS R-CHOP IN THE FIRST-LINE TREATMENT OF PATIENTS WITH INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) - PRELIMINARY ANALYSIS
    Hainsworth, J. D.
    Arrowsmith, E. R.
    Mccleod, M.
    Fayad, L. E.
    Hamid, O.
    Davis, L.
    Lin, B.
    ANNALS OF ONCOLOGY, 2011, 22 : 107 - 107
  • [24] Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
    Younes, Anas
    Sehn, Laurie H.
    Johnson, Peter
    Zinzani, Pier Luigi
    Hong, Xiaonan
    Zhu, Jun
    Patti, Caterina
    Belada, David
    Samoilova, Olga
    Suh, Cheolwon
    Leppae, Sirpa
    Rai, Shinya
    Turgut, Mehmet
    Jurczak, Wojciech
    Cheung, Matthew C.
    Gurion, Ronit
    Yeh, Su-Peng
    Lopez-Hernandez, Andres
    Duehrsen, Ulrich
    Thieblemont, Catherine
    Chiattone, Carlos Sergio
    Balasubramanian, Sriram
    Carey, Jodi
    Liu, Grace
    Shreeve, S. Martin
    Sun, Steven
    Zhuang, Sen Hong
    Vermeulen, Jessica
    Staudt, Louis M.
    Wilson, Wyndham
    Fisher, Richard I.
    Engert, Andreas
    Stadtmauer, Edward A.
    Wei, Lee-Jen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15) : 1285 - +
  • [25] Prognostic significance of primary extranodal diffuse large B-cell lymphoma (DLBCL) in patients treated with R-CHOP
    Hui, D.
    Proctor, B.
    Donaldson, J.
    Shenkier, T.
    Hoskins, P.
    Klasa, R.
    Savage, K.
    Gascoyne, R.
    Connors, J. M.
    Sehn, L. L.
    ANNALS OF ONCOLOGY, 2008, 19 : 186 - 187
  • [26] A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma
    Cunningham, D.
    Smith, P.
    Mouncey, P.
    Qian, W.
    Pocock, C.
    Ardeshna, K. M.
    Radford, J.
    Davies, J.
    McMillan, A.
    Linch, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Prognostic significance of primary extranodal diffuse large B-cell lymphoma (DLBCL) in patients treated with R-CHOP
    Proctor, B. R.
    Hui, D.
    Donaldson, J.
    Savage, K. J.
    Shenkier, T. N.
    Hoskins, P. J.
    Klasa, R.
    Randy, G.
    Joseph, C.
    Sehn, L. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy
    Li, Zhi-Ming
    Huang, Jia-Jia
    Xia, Yi
    Zhu, Ying-Jie
    Zhao, Wei
    Wei, Wen-Xiao
    Jiang, Wen-Qi
    Lin, Tong-Yu
    Huang, Hui-Qiang
    Guan, Zhong-Zhen
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 88 (06) : 510 - 517
  • [29] Orelabrutinib Plus R-CHOP Regimen in Treatment-Naive Patients with TP53-Mutated Diffuse Large B-Cell Lymphoma (DLBCL)
    Xiao, Yi
    Wu, Jiaying
    Zhou, Mi
    Shang, Zhen
    Zhu, Ming
    BLOOD, 2023, 142
  • [30] Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes
    Saad, Abeer A.
    Awed, Nahla M.
    Abdel-Hafeez, Zeinab M.
    Kamal, Gihan M.
    Elsallaly, Hala M.
    Alloub, Amal I.
    SAUDI MEDICAL JOURNAL, 2010, 31 (02) : 135 - 141
12345